Investor desk
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ScopeX.
← Back to Events
Tier 1 Global Networking: High GENERAL CONCLUDED
ScopeX — 2026 — Not specified, Boston, USA
On Wednesday, April 29, 2026, the FDA is hosting a free public webinar to provide updates on RCT-DUPLICATE, one of FDA’s demonstration projects addressing key methodological challenges in studies using real-world data (RWD). This webinar will highlight how the RCT-DUPLICATE initi
3 Presentations
3 Companies
3 Drugs
Presentation data updated Jun 12, 2026, 5:34 AM UTC
Why This Event Matters
On Wednesday, April 29, 2026, the FDA is hosting a free public webinar to provide updates on RCT-DUPLICATE, one of FDA’s demonstration projects addressing key methodological challenges in studies using real-world data (RWD).
Industry impact
On Wednesday, April 29, 2026, the FDA is hosting a free public webinar to provide updates on RCT-DUPLICATE, one of FDA’s demonstration projects addressing key methodological challenges in studies using real-world data (RWD).
Market implications
Expect signals on pricing, formulary strategy, and partnership economics relevant to general markets in the US region.
Regulatory implications
FDA and CMS policy discussions around evidence generation, 340B, and real-world data often surface at general leadership forums.
Investor implications
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ScopeX.
Competitive implications
Competitive positioning among top general players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Event Significance
Tier-1 industry catalyst
60 /100 composite
ScopeX is a targeted general forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: downstream media and analyst follow-through.
- Media coverage 20/20
High follow-on media and sell-side note volume expected within 24–48h of key sessions.
- Speaker quality 14/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Pipeline relevance 0/20
Early science or services-focused — lower near-term PDUFA linkage.
- Historical influence 20/20
Prior editions moved stock prices and label expansions — expect similar volatility windows.
- Company participation 6/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
Nova Pharma Intelligence · Analyst desk
Key Takeaways
- Watch oral (Nuvalent · neladalkib): Pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from the ALKOVE-1 study
- Watch poster (AstraZeneca · durvalumab + tremelimumab): Phase III HIMALAYA data readout: Imfinzi + Imjudo in 1L HCC
- Watch poster (RenovoRx · gemcitabine): RenovoRx Phase III trial update: TACE plus RenovoGem in pancreatic cancer
- AstraZeneca carries 1 tracked presentations — map against peer readouts at ScopeX.
- Nuvalent carries 1 tracked presentations — map against peer readouts at ScopeX.
- durvalumab + tremelimumab (AstraZeneca) — 1 data points on the schedule.
Timeline & Milestones
- Pre-event intelligence Complete
3 presentations tracked — Key Data and Companies hubs live.
- Conference opens May 18, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
1 Nova articles linked — see Coverage & Analysis.
- Conference closes May 19, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
Investors & analysts
Executive Summary
C-level briefOn Wednesday, April 29, 2026, the FDA is hosting a free public webinar to provide updates on RCT-DUPLICATE, one of FDA’s demonstration projects addressing key methodological challenges in studies using real-world data (RWD).
Primary audience: Investors & analysts
Analyst Watch
Regulatory affairs
FDA and CMS policy discussions around evidence generation, 340B, and real-world data often surface at general leadership forums.
Competitive intelligence
Competitive positioning among top general players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Most Anticipated Presentations
Full data hub → ORAL
Pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from the ALKOVE-1 study
POSTER
Phase III HIMALAYA data readout: Imfinzi + Imjudo in 1L HCC
POSTER
RenovoRx Phase III trial update: TACE plus RenovoGem in pancreatic cancer
Competitive Landscape
Company map →Competitive positioning among top general players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Companies to Watch
All companies →Drug Pipelines to Watch
Pipeline data →Related Clinical Trials
1 NCT IDs- NCT03298451 Phase III HIMALAYA data readout: Imfinzi + Imjudo in 1L HCC
Coverage & Analysis
1 articlesRelated News & Research
Research hub →Event Intelligence Summary
Standalone summaries for ScopeX — optimized for research and AI retrieval.
Executive Summary
On Wednesday, April 29, 2026, the FDA is hosting a free public webinar to provide updates on RCT-DUPLICATE, one of FDA’s demonstration projects addressing key methodological challenges in studies using real-world data (RWD).
Analyst View
On Wednesday, April 29, 2026, the FDA is hosting a free public webinar to provide updates on RCT-DUPLICATE, one of FDA’s demonstration projects addressing key methodological challenges in studies using real-world data (RWD).
Investor View
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ScopeX.
BD View
BD teams should prioritize networking with presenting companies and services vendors at ScopeX, focusing on general partnership and licensing opportunities.
Key Facts
- Event
- ScopeX
- Focus
- general
- Region
- US Americas
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is ScopeX?
ScopeX is a general industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Who attends ScopeX?
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on general.
Why is ScopeX important?
ScopeX influences partnership timing, pipeline prioritization, and policy debates that affect general markets for the next 12–18 months.
When is ScopeX?
ScopeX takes place on the scheduled dates.
Where is ScopeX held?
ScopeX is held in the listed venue.
What companies participate at ScopeX?
3+ companies present data or participate in programming at ScopeX, spanning large pharma, biotech, and services vendors.
What should investors watch at ScopeX?
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on general catalysts during and after ScopeX.
What BD opportunities exist at ScopeX?
BD teams use ScopeX for licensing discussions, co-development talks, and vendor selection across general — especially in networking sessions and satellite meetings.
How does ScopeX compare with other pharma conferences?
ScopeX is a tier-1 global congress for general — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
How do I get NovaPharmaNews coverage of ScopeX?
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for ScopeX. Subscribe to event alerts on this page for breaking updates.